A record year for Paxman!

Figures in parentheses refer to results during the corresponding period of the previous year. Note that the figures for Q4 2022 were affected by large movements in currency adjustments when preparing the financial statements.

• The group’s turnover amounted to SEK 55.6 (40.7) million during the fourth quarter of the year.

• During the year, turnover totaled SEK 210 M (146).

• The net result amounted to SEK -1.6 (-9.8) million for the period October-December, which resulted in a net result of a total of SEK 8.3 (-10.3) million for the full year.

• EBITDA amounted to SEK 9.5 (12.8) million for the period October-December and to SEK 31.2 (16.2) million for the full year.

• Earnings per share amounted to SEK -0.09 (-0.51) for the period October-December and to SEK 0.44 (-0.54) for the whole year.

• The period’s cash flow amounted to SEK 722 thousand, of which SEK 7.8 (-0.9) million was from current operations. For the full year, the cash flow from current operations amounted to SEK 15.6 (1.7) million.

• Number of systems installed during the year amounted to 601 (528), with a further 154 (217) systems in the order book.

• Average daily treatment revenue (ADTR) amounted to USD 35.2 thousand (SEK 377 thousand) during Q4 2023, which corresponds to an increase of 23.6% compared to USD 28.8 thousand (SEK 306.1 thousand) for Q4 2022. The figures in SEK have converted to USD according to the actual exchange rate during the respective period.

• Current income increased from SEK 22.7 M for Q4 2022 to SEK 28.1 M for the same period in 2023.